#esmo21 highlights on patterns of relapse in nsclc to atezolizumab vs bsc after adj ct: impower010
Published 2 years ago • 1.8K plays • Length 3:27Download video MP4
Download video MP3
Similar videos
-
2:59
#esmo21 highlights on atezolizumab combined with folfoxiri bev in 1st-line mcrc: atezotribe study
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:19
#esmo21 highlights on pembrolizumab in fully resected high-risk stage ii melanoma: keynote-716 study
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
5:50
#esmo21 expert video report on novelties in metastatic nsclc
-
6:09
expert video report on therapeutic advances in nsclc from 2021 asco annual meeting
-
14:00
asco 2021 lung recap: impower010: atezolizumab after chemo in non-small cell lung cancer
-
2:47
#esmo21 highlights on erdafitinib in adv. urothelial cancer with fgfra alterations: the norse study
-
3:09
#esmo21 highlights on nivo ipi vs extreme in 1st-line high-risk scchn: the checkmate 651 study
-
1:41
#esmo21 highlights on nivolumab in pretreated thymoma & thymic carcinoma: eortc-etop nivothym study
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study
-
1:35
#esmo21 highlights on a phase i of dual raf/mek inhibitor fak inhibitor in ovarian cancer (frame)
-
2:51
#esmo21 highlights on adagrasib in patients with krasg12c-mutated crc: the krystal-1 study
-
9:24
impower010 supports adjuvant atezolizumab in early-stage nsclc | heather wakelee
-
2:30
#esmo21 highlights on gemcitabine vs mfolfirinox in resected pancreatic cancer: prodige 24/cctg pa6
-
1:54
highlights in lung cancer at esmo 2022
-
1:50
dr. melissa johnson on atezolizumab in patients with nsclc